Moreover, patients who had an increase in sPD-L1 concentrations between nivolumab initiation and first tumor evaluation had worse ORR (17% vs. 68%, p = 0.005), lower rates of clinical benefit (10% vs. 47%, p = 0.047), shorter median PFS (1.8 months vs. 6.5 months, p = 0.008), and shorter median OS (5.4 months vs. NR, p = 0.028) than patients who had decreasing or stable sPD-L1 concentrations. This evidence concerns the gene SPDL1 and neoplasm.